Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845871 · ClinicalTrials.gov registry record · Phase 4
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT00845871 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 65 participants.
The verdict
NCT00845871, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
This single-arm, open-label, multi-center study enrolled 65 patients from approximately 20 centers. All patients who met the study criteria and were taking, beginning or resuming treatment with Deferasirox were allowed. The study will began with a one month run-in phase, where all patients were instructed to take Deferasirox according to their physician's prescribing information.
Interventions
- DRUG deferasirox:
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845871
The ClinicalTrials.gov registry entry for NCT00845871 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which deferasirox: is the first listed.
NCT00845871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00845871 about?
NCT00845871 is a clinical study titled "Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food". This single-arm, open-label, multi-center study enrolled 65 patients from approximately 20 centers. All patients who met the study criteria and were taking, beginning or resuming treatment with Deferasirox were allowed. The study will began with a one month run-in phase, where all patients were inst...
What is the current status of trial NCT00845871?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2009-05. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00845871?
The interventions under investigation include: deferasirox: (DRUG).
Who is sponsoring clinical trial NCT00845871?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.